Replanteamiento de la expresión de CLDN18.2 en el tratamiento del cáncer gástrico - Respuesta de los autores

Chang Liu1, Zhi Peng2, Changsong Qi3

  • 1Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumour, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Early Drug Development Centre, Peking University Cancer Hospital & Institute, Beijing, China.

Lancet (London, England)
|January 10, 2026
PubMed
Resumen

No abstract available in PubMed .